Clinical Trials Logo

Clinical Trial Summary

Clinically Characterized by the presence of chronic widespread pan and tenderness, Fibromyalgia (FM) is one of the most common "functional" syndromes. FM is currently conceived of as representing a prototype of central pain, i.e. a condition in which sensitization of the central nervous system results in a overall increase in the processing of painful stimuli, as well as an impairment of pain inhibition. This condition is responsible for significant a social and economic burden and is estimated to affect up to 5% of all women. The 1990 American College of Rheumatology (ACR) classification criteria for FM are the current standard for studying FM, and require the presence of widespread pain lasting over 3 months, as well as documentation of tenderness in at least 11 of 18 pre-defined "tender points. Multiple additional symptoms, which are not part of the classification criteria, include among others sleep disturbances, mood disturbances, cognitive dysfunction, vulvodynia, dysmenorrhea, sexual dysfunction and weight fluctuations. In addition, FM is well known to overlap both clinically and epidemiologically with an ever increasing number of other "functional" disorders, including irritable bowel syndrome (IBS), Temporomandibular joint disorder (TMJD), functional dyspepsia etc. In addition to the central symptom of pain, FM patients frequently complain of non- specific symptoms which are potentially autonomically - mediated. Thus, palpitations, fatigue and inability to stand for long periods of time are all common complaints. About 80-90 percent of FM patients have one or more symptoms associated with autonomic dysfunction. The most common of them is presyncope (62.5%), followed by syncope (12.5%), palpitations on standing (12.5%) and dizziness (12.5%) (14). Some of these symptoms overlap with those of the postural tachycardia syndrome (POTS). POTS is a common dysautonomia, characterized by remarkable increased heart rate during the assumption of the upright posture (>30 bpm). According to our experience, FM is found, at least, in 15% of POTS patients. But, no data exists about the incidence of POTS in patients with FM.The role of the autonomic nervous system (ANS) in initiating and maintaining the syndrome of FM has been studies (and debated) over the last decade. The ANS is an extremely complex system, regulating involuntary body functions, including heart rate, intestinal motility, urination, and sexual activity, among many other variables. Notably, the vagus has an inhibitory effect on pain. Deterioration in the vagal control is "associated" with increased pain sensation. Previous studies have indicated that FM patients may have an increase in sympathetic control over the cardiovascular system with a reciprocal decrease in parasympathetic control. High sympathetic tone is usually associated with a lower threshold to pain. But, the contribution of the ANS to the pathogenesis of FM syndrome remains unclear. Evidently, the ANS interacts with other components of the CNS in the pathogenesis of FM, including pain processing centers in the thalamus and amygdala, as well as with the hypothalamic-pituitary-adrenal (HPA) axis.


Clinical Trial Description

n/a


Study Design

Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01147263
Study type Observational
Source Tel-Aviv Sourasky Medical Center
Contact Jacob N Ablin, MD
Phone 972-3-6973668
Status Not yet recruiting
Phase N/A
Start date July 2010
Completion date June 2012

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05933486 - Efficacy and Safety of Tongluo-Kaibi Tablet in Patients With Fibromyalgia Syndrome Phase 4
Completed NCT01642810 - Online Acceptance-based Behavioural Treatment for Fibromyalgia Phase 3
Completed NCT00757731 - FMS European Long-Term Study Phase 3
Completed NCT00757679 - Evaluation of the Antinociceptive and Analgesic Effects of Milnacipran Phase 2
Completed NCT01968772 - Effect of Transdermal Magnesium Chloride on Quality of Life in Patients With Fibromyalgia N/A
Completed NCT00401830 - Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome. Phase 2
Completed NCT04517929 - Effectiveness of Group Psychotherapy in Patients With Fibromyalgia Syndrome N/A
Completed NCT06285045 - Study on Roujin Formula in the Treatment of Fibromyalgia Syndrome With Blood Deficiency and Liver Depression N/A
Recruiting NCT03844412 - Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments Phase 2
Completed NCT02800720 - Meditation Awareness Training for the Treatment of Fibromyalgia Syndrome N/A
Not yet recruiting NCT01465477 - Influenza Vaccination in Fibromyalgia Patients N/A
Completed NCT00528710 - Efficacy of S-Adenosylmethionine in Fibromyalgia Phase 2
Completed NCT00447083 - Benefits of Tanning in Fibromyalgia Patients N/A
Not yet recruiting NCT06147882 - The Effect of Positive Psychotherapy Based Psychoeducation on Pain Perception With Fibromyalgia Syndrome N/A
Completed NCT05381012 - Fibromyalgia Syndrome on Patients With Chronic Migraine N/A
Completed NCT00464737 - The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults. Phase 2
Completed NCT04426864 - Efficacy of Different Types of Exercises in Women With Fibromyalgia Syndrome. N/A
Completed NCT02881411 - Self Soft Tissue Therapy for Fibromyalgia Syndrome N/A
Completed NCT01389336 - Add-on Complex Ayurvedic Treatment in Fibromyalgia-Syndrome Compared to Standard Care Alone N/A
Completed NCT00222274 - HRV Biofeedback in Fibromyalgia N/A